enzh-TWfrdeitjaptrues

Your privacy is important to us, so we operate the site by the following principles:

Confidentiality
You may use our site without disclosing personally identifiable information. We want to be clear that we will not obtain such information about you unless you choose to submit it to us. If you supply personally identifiable information (such as name, address or telephone numbers) for various purposes on this site, we only use the information for that purpose (such as to provide the service or information you have requested).

Security
The Dana-Farber Waldenstrom's Macroglobulinemia Program takes every precaution to protect our users' information. When a registration/order form asks users to enter sensitive information (such as credit card number and/or diagnosis), that information is encrypted and is protected with the best encryption software in the industry- SSL.

Should you electronically request a referral to a Dana-Farber physician, we will use the information you submit to arrange for care where appropriate. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off line. Our software and hardware is configured to provide maximum security.

To use our contact form, the Magic Word is Bing.

Cookies
The Dana-Farber Waldenstrom's Macroglobulinemia Program Web sites use cookies to track traffic coming to our site. We do not collect personal data such as name, age, phone number, e-mail, or mailing address. Cookies will also be used to identify a person who chooses to register on our site. If you choose to register on our site and are given a password for an event, give donations on line, or choose to enroll in our e-mail subscription services, we will identify you with cookies. You will always have a chance to opt out at any time.

Information Collection and Use
The Dana-Farber Waldenstrom's Macroglobulinemia Program is the sole owner of the personal medical information collected on this site. We will not sell, share, or rent this information to others. The Dana-Farber occasionally trades its contributor mailing lists with other non-profit organizations. This process saves us money and is carefully monitored and one may always opt-out.

Donations on the Web
When you make a gift on our site, your e-mail will be entered into our donor database. We may send you e-mails or mailings in the future informing you of other giving opportunities or providing news about The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia. If you choose not to receive any further communication from us, you may opt-out by e-mailing This email address is being protected from spambots. You need JavaScript enabled to view it. or calling our offices at 1-617-632-6285.

Latest Bing Center News

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

Clinical Trials Are Moving Out of the Lab and Into Peopleʼs Homes

After the pandemic forced thousands of trials to shut down, researchers found clever ways to conduct human studies remotely — while reaching more people, quickly and cheaply.

Read more..

Current and Future Treatments for Waldenstrom Macroglobulinemia

Current and Future Treatments for Waldenstrom Macroglobulinemia

What are the treatments for Waldenstrom macroglobulinemia and what's in the pipeline? Can Waldenstrom patients plan for a higher quality of life? Dr. Jorge Castillo, Clinical Director, Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, presents an overview of his presentation at the 2020 IWMF with Patient Power co-founder Andrew Schorr.

Read more..

Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)

Progress in the Treatment of Waldenstrom’s Macroglobulinemia (Webcast)

Workshop Date and Time: Wednesday, April 21, 2021, 12:30 – 1:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast.

Read more..

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Despina Fotiou and Meletios A. Dimopoulos present a summary of trial findings and details regarding various BTK inhibitors, including ibrutinib, zanubrutinib, acalabrutinib, tirabrutinib, LOXO-305, etc.

Read more..

BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia

BeiGene (BGNE) Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA in Waldenstrom's Macroglobulinemia

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA® (zanubrutinib) for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM). The Prescription Drug User Fee Act (PDUFA) target action date is October 18, 2021.

Read more..

Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!

Podcast with Dr. Jorge Castillo: MGUS, Myeloma, WM AND Immunology, Oh My!

December 21, 2020: Dr. Jorge Castillo walks us through immunology basics, teaches us the limitations of the SPEP, plus some additional tests that complement it (think Immunofixation), shares his clinical gestalt about when to suspect MGUS, Myeloma, Waldenstrom’s, and Amyloidosis–and finally, how to talk to patients about them.

Read more..

International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions

International Myeloma Society Recommendations for Covid-19 vaccinations in patients with MM and related conditions

Dear IMS Member: We hope you are well during these difficult times. As a response to the current pandemic, the International Myeloma Society has developed the following Recommendations for anti-Covid-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance.

Read more..

Cancer and the COVID-19 Vaccine

Cancer and the COVID-19 Vaccine

On January 27, Dana Farber held a webinar to review the information regarding COVID-19 vaccinations for patients. Catherine Flynn (from the Bing Center Clinic) shares the following highlights from the webinar.  Note, the entire webinar was recorded and posted to Facebook, using the following link:

Read more..

COVID-19 Facts and Resources

COVID-19 Facts and Resources

Based on the latest guidance we have received from the state of Massachusetts, we expect Dana-Farber's supply of COVID-19 vaccine for patients to be very limited in February and perhaps longer. We are working hard to place special focus on getting vaccines to our most at-risk patients, in compliance with the state's rollout guidelines, as we receive allotments of the vaccine.

Read more..

Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update

Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update

Please join the Center for Multiple Myeloma for a free webinar for patients and families to learn about the most recent updates in muliple myeloma and Waldenstrom's macroglobulinemia including the impact of COVID-19 and vaccination.

Read more..